Industry dynamics are shifting in the wake of Zimmer's Biomet acquisition.
Diversified foreign-stock funds with ample emerging-markets exposure offer a great entry point into developing regions.
Stock returns since October 2007 have been flat, but these funds have been anything but.
Plus, a small-cap favorite reopens, changes at Oak Value, and more.
A clear view of the present is the only thing that Richard Bregman thinks can guide his investment decisions.